Lin Yu-Hsin 4

What Happened
Lin Yu‑Hsin, CEO of Belite Bio, sold a total of 9,200 American depositary shares (ADS) in open-market transactions on April 9, 2026, for total proceeds of $1,669,339. The individual trades reported: 2,500 ADS @ $180.36 ($450,895); 3,500 ADS @ $181.33 ($634,656); 3,000 ADS @ $182.40 ($547,188); and 200 ADS @ $183.00 ($36,600). These were sales (not purchases) and therefore generally represent liquidity by the insider rather than a bullish purchase signal.

Key Details

• Transaction date: 2026-04-09; Form 4 filed: 2026-04-13 (timely within required reporting window).
• Total shares sold: 9,200 ADS; total proceeds: $1,669,339.
• Reported prices: $180.36, $181.33, $182.40, $183.00 (file footnotes indicate weighted-average reporting across small price ranges).
• Footnotes of note:
  • ADS conversion: each ADS represents one ordinary share (F1).
  • Sales were made pursuant to a Rule 10b5‑1 trading plan adopted by the reporting person on 12/23/2025 (F2).
  • F3–F5 explain that some reported amounts reflect weighted-average prices across specified price ranges and that the filer will provide per-price sale counts on request.
• Shares owned after the transaction: not specified in the supplied filing data.

Context
These transactions were sales executed under a pre-established 10b5‑1 plan, which allows insiders to sell according to a predetermined schedule and is commonly used to avoid questions about trading on material nonpublic information. The filing appears timely (filed within two business days of the trade date). As always, sales by executives are factual disclosures of insider activity; they do not on their own prove management sentiment about the company’s prospects.